VAXCELL BIO THERAPEUTICS
Vaxcell Bio Therapeutics is an pharmaceutical firm that develops anti-cancer drugs, cellular drugs, immune drugs, and other medicines.
VAXCELL BIO THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2010-02-18
Address:
Hwasun, Cholla-namdo, South Korea
Country:
South Korea
Website Url:
http://www.vaxcell-bio.com
Total Employee:
51+
Status:
Active
Contact:
+82 061-373-0046
Technology used in webpage:
SPF SSL By Default Nginx DigiCert SSL Thawte SSL SK Broadband
Similar Organizations
Hishoh Biopharma
Hishoh Biopharma develops a new generation of Allergen Immunotherapy based on robust scientific evidence.
Ichorion Therapeutics
Ichorion Therapeutics is a biopharmaceutical company that develop treatments for rare diseases with unmet medical needs.
Jisi Yingda
Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development.
SparX Therapeutics
SparX Therapeutics is a biopharmaceutical firm that develops smart drug technology for anti-cancer and anti-tumor treatment therapy.
Velox Biologics
Velox Biologics is a pharmaceutical company that provides anticonvulsants, antiemetics, and antibiotics.
Stock Details
Investors List
HB Investment
HB Investment investment in Post-IPO Equity - Vaxcell Bio Therapeutics
Dayli Partners
Dayli Partners investment in Post-IPO Equity - Vaxcell Bio Therapeutics
Official Site Inspections
http://www.vaxcell-bio.com Semrush global rank: 3.93 M Semrush visits lastest month: 2.86 K
- Host name: 183.111.174.41
- IP address: 183.111.174.41
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Vaxcell Bio Therapeutics"
Vaxcell Bio Therapeutics - Crunchbase Company Profile โฆ
Vaxcell Bio Therapeutics is an pharmaceutical firm that develops anti-cancer drugs, cellular drugs, immune drugs, and other medicines. View contacts for Vaxcell Bio Therapeutics to access new leads and connect with decision-makers.See details»
Vaxcell Bio Company Profile 2024: Stock Performance โฆ
Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer. Contact Information WebsiteSee details»
VaxCell Biotherapeutics Co., Ltd. | LinkedIn
VaxCell Biotherapeutics Co., Ltd. | 42 followers on LinkedIn. The Better life with Anti-cancer immunotherapy | [Vision] ๋ฐ์ ๋ฐ์ด์ค๋ ํญ์ ๋ฉด์ญ ์น๋ฃ๋ฅผ ํตํ ๋ ๋์ ์ถ์ ...See details»
Vaxcell-Bio Therapeutics Co Ltd - Company Profile and News
Vaxcell-Bio Therapeutics, Co. Ltd operates pharmaceutical development businesses. The Company develops anti-cancer drugs, cellular drugs, immune drugs, and other medicines.See details»
Vaxcell-Bio Therapeutics Annual Report - fss.or.kr
Entity Registrant Name : Vaxcell-Bio Therapeutics: Entity Legal Registration Number : 205211-0029832: Entity Fiscal Month : December: Number Of Employee : 25Person Number Of โฆSee details»
Vaxcell-Bio Therapeutics Company & People | 323990 - Barron's
Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. It specializes in immune cell therapy. The company was founded by Lee Jae-Jung on February 18, 2010 and is headquartered in...See details»
Vaxcell-Bio Therapeutics Company Profile & Executives - WSJ
Company profile for Vaxcell-Bio Therapeutics including key executives, insider trading, ownership, revenue and average growth rates. View detailed 323990.KR description & address.See details»
Vaxcell-Bio Therapeutics Co. Ltd. - BioCentury Company Profiles
Vaxcell-Bio Therapeutics Co. Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
Vaxcell-Bio Therapeutics Research & Ratings | 323990 - Barron's
Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. It specializes in immune cell therapy. The company was founded by Lee Jae-Jung on February 18, 2010 and is headquartered in...See details»
Vaxcell-Bio Therapeutics ESG Risk Rating - Sustainalytics
Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer. Full time employees: 74 โฆSee details»
Vaxcell-Bio - Products, Competitors, Financials, Employees ...
Vaxcell-Bio develops cell-based anticancer immunotherapy drugs, anticancer vaccines, and anticancer protein drugs. It is based in South Korea. You're one click away from the most โฆSee details»
323990 Stock Price Quote | Morningstar
See the latest Vaxcell-Bio Therapeutics Ordinary Shares stock price (323990:XKRX), related news, valuation, dividends and more to help you make your investing decisions.See details»
Vaxcell Bio Therapeutics (323990) Stock Price & News - Google
Get the latest Vaxcell Bio Therapeutics (323990) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.See details»
VAX-DC/MM - AdisInsight - Springer
Mar 19, 2021ย ยท Vax-DC/MM is an dendritic vaccine being developed by VaxCell-Bio Therapeutics for the treatment of multiple myeloma. Vax-DC/MM is generated by dendritic cells.See details»
Lenalidomide and Programmed Death-1 Blockade Synergistically โฆ
Jun 18, 2018ย ยท In this study, we investigated the efficacy of DC vaccination in combination with lenalidomide and programmed death (PD)-1 blockade in a model of murine myeloma.See details»
A Phase I Study of Locoregional High-Dose Autologous Natural โฆ
Jun 2, 2022ย ยท Background: To explore the feasibility and safety of natural killer (NK) cell therapy in HCC, we performed a prospective, open-label, phase I trial to evaluate the synergistic effect of โฆSee details»
323990 | Vaxcell-Bio Therapeutics Stock Overview (S. Korea: KRX ...
Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. It specializes in immune cell therapy. The company was founded by Lee Jae-Jung on February 18, 2010 and is headquartered in...See details»
Frontiers | A Phase I Study of Locoregional High-Dose Autologous ...
Jun 1, 2022ย ยท In the current study, we aimed to evaluate the safety and efficacy of locoregional high-dose autologous NK cells (VAX-NK/HCC) generated by our novel system in combination โฆSee details»
Dendritic Cell-Based Cancer Immunotherapy against Multiple
We developed a method to generate potent DCs with increased Th1 polarization and migration ability for inducing strong myeloma-specific cytotoxic T lymphocytes. In this review, we discuss โฆSee details»
Potent anti-myeloma efficacy of dendritic cell therapy in ... - PubMed
Blocking of PD-L1 on DC may lead to improve the efficacy of DC therapy for cancer. Here we demonstrated that DC vaccination in combination with pomalidomide and programmed death โฆSee details»